Zelluna doses first patient in Phase 1 ZI-MA4-1 solid tumor trial ZIMA-101

• Zelluna dosed the first patient in ZIMA-101, a first-in-human Phase 1 trial of its lead TCR-NK therapy candidate ZI-MA4-1.
• ZI-MA4-1 targets MAGE-A4 in advanced solid tumors, marking the first clinical test of Zelluna’s proprietary TCR-NK platform.
• First clinical data are expected from mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zelluna ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607131108OMX_____CNEWS_NO_GNW1001212594_no) on July 13, 2026, and is solely responsible for the information contained therein.